Registration Dossier

Toxicological information

Repeated dose toxicity: dermal

Currently viewing:

Some information in this page has been claimed confidential.

Administrative data

short-term repeated dose toxicity: dermal
Type of information:
other: the tested substance is the amine of the compound
Adequacy of study:
key study
2 (reliable with restrictions)
Rationale for reliability incl. deficiencies:
other: Acceptable well-documented publication which meets basic scientific principles.

Data source

Referenceopen allclose all

Reference Type:
Reference Type:
study report
Report Date:

Materials and methods

Test guideline
according to
OECD Guideline 410 (Repeated Dose Dermal Toxicity: 21/28-Day Study)
Principles of method if other than guideline:
For the dermal toxicity study, 0, 100, 500 or 750 mg DIPA/kg/day was applied to an approximately 2x2 cm interscapular-dorsal area of groups of five Fischer 344 rats/sex/dose level 5 days/week for 4 weeks. Application site skin was clipped free of hair, covered with an occlusive wrap during the dosing period each day, and was reclipped as necessary during the dosing period. The wraps were removed after 6 h and the treated sites were washed by gentle padding with watersoaked gauze. Skin site of application was graded at the end of each week and the dosing period for erythema and eschar, edema, scaling and fissuring, and presence of scabs using a modification of the scoring system recommended by OECD (1981).
GLP compliance:
Limit test:

Test material

Details on test material:
- Name of test material (as cited in study report): Diisopropanolamine- Analytical purity: ranged from 98.8 % - 99.6 %

Test animals

Fischer 344/DuCrj
Details on test animals and environmental conditions:
TEST ANIMALS- Source: Charles River Laboratories Inc. (Kingston, New York and Raleigh, North Carolina)- Diet: LabDiet #5002 Certified Rodent Diet (PMI Nutrition International, St. Louis, MO) ad libitum- Water: tap water ad libitumENVIRONMENTAL CONDITIONS- Temperature (°C): 21-25 °C- Humidity (%): 45-60 %- Air changes (per hr): 12-15- Photoperiod (hrs dark / hrs light): 12/12

Administration / exposure

Type of coverage:
Details on exposure:
TEST SITE- Area of exposure: 2x2 cm- Time intervals for shavings or clipplings: at the beginning and also reclipped as necessary during the dosing period.REMOVAL OF TEST SUBSTANCE- Washing (if done): by gentle padding with watersoaked gauze.- Time after start of exposure: 6 h
Analytical verification of doses or concentrations:
Duration of treatment / exposure:
4 weeks
Frequency of treatment:
5 days/week
Doses / concentrations
Doses / Concentrations:0, 100, 500, 750 mg/kg bw/dayBasis:nominal per unit body weight
No. of animals per sex per dose:
Control animals:
yes, concurrent vehicle


Observations and examinations performed and frequency:
CAGE SIDE OBSERVATIONS: Yes - Time schedule: twice dailyDETAILED CLINICAL OBSERVATIONS: Yes- Time schedule: weeklyBODY WEIGHT: Yes- Time schedule for examinations: weeklyFOOD CONSUMPTION: - Food consumption for each animal determined and mean daily diet consumption calculated as g food/kg body weight/day: Yes WATER CONSUMPTION: Yes- Time schedule for examinations: weeklyHAEMATOLOGY: Yes - Time schedule for collection of blood: at necropsy- Anaesthetic used for blood collection: Yes with methoxyflurane or CO2- Animals fasted: No data- How many animals: allCLINICAL CHEMISTRY: Yes - Time schedule for collection of blood: at necropsy- Animals fasted: No data- How many animals: allStandard hematologic and clinical chemistry parameters were evaluated consistent with globally accepted regulatory guidelines (EEC, 1992; EPA, 1998; OECD, 1998; MITI, 1988).URINALYSIS: Yes - Time schedule for collection of urine: near end of study- Metabolism cages used for collection of urine: No data- Animals fasted: NoStandard urinalysis parameters were evaluated (EEC, 1992; EPA, 1998; OECD, 1998; MITI, 1988).
Sacrifice and pathology:
GROSS PATHOLOGY: Yes HISTOPATHOLOGY: Yes; Histopathologic examination was conducted on selected organs
Consistent with the variety of data collected, a large number of statistical methods were employed. Means and standard deviations were calculated for all continuous data. These parameters were first examined for equality of variance using Bartlett’s test (a = 0.01; Winer, 1971). If the results of the Bartlett’s test were significant, the data were transformed in an attempt to obtain equality of variances. The order of transformations used was the common log, the inverse and the square root with the best fit used for subsequent statistical testing. Weekly body weights were analyzed using a 3-way repeated ANOVA, with body weights the repeated measure and Dunnett's test for comparison to controls; terminal body weight organ weights, clinical pathology parameters and urine specific gravity were evaluated using 2-way ANOVA, separate 1-way ANOVA for each sex if sex by dose significant Dunnett's test for comparison to controls. As statistical interactions (i.e., time by dose or sex by dose) were identified in several of the tests, the alpha levels for interaction terms were set a priori at 0.01–0.10, with Bonferroni’s correction. The alpha level for comparison of individual dose groups to controls was set a priori at 0.05.

Results and discussion

Results of examinations

Details on results:
CLINICAL SIGNS AND MORTALITYAll rats survived the study period and there were no treatment-related effects.BODY WEIGHT AND WEIGHT GAINno treatment related effects.FOOD CONSUMPTIONno treatment related effects.WATER CONSUMPTIONno treatment related effects.HAEMATOLOGYno treatment related effects.CLINICAL CHEMISTRYno treatment related effects.URINALYSISno treatment related effects.ORGAN WEIGHTSno treatment related effectsGROSS PATHOLOGYerythema was noted for all five males and three females treated with 750 mg/kg/day and two males and two females treated with 500 mg/kg/day. The erythema was graded as very slight (barely perceptible) for all rats except for one female treated with 500 mg/kg/day and one treated with 750 mg/kg/day in which erythema was graded as slight (well-defined) at one time during the study.HISTOPATHOLOGY: NON-NEOPLASTICslight hyperkeratosis of the treated site in all rats given 750 mg/kg/day and very slight hyperkeratosis in two males and two females given 500 mg/kg/day.

Effect levels

open allclose all
Dose descriptor:
systemic toxicity
Effect level:
750 mg/kg bw/day
Basis for effect level:
other: no systemic effects were reported
Dose descriptor:
local toxicity
Effect level:
100 mg/kg bw/day
Basis for effect level:
other: dermal irritancy (100 mg/kg bw/day corresponds to 0.8 mg/cm2 assuming a body weight of 0.2 kg and as 25 cm2 skin was exposed)

Target system / organ toxicity

Critical effects observed:
not specified

Any other information on results incl. tables

Effects of DIPA applied dermally to F344 rats for 4 weeks:

 Parameter  Dose level (mg/kg/day)                     
   males           females         
   0  100  500  750  0  100  500  750
 Terminal body weight (g)  213.7  219.7  218.7  213.2  135.2  137.9  135.6  136.1
 Serum urea nitrogen (mg/dL)  20 19  20  20  17  17  16  18 
 Kidney weight (g)  1.661  1.724  1.703  1.676  1.116  1.113  1.119 1.127 
 rel. kidney weight (g/100g)  0.777  0.786  0.779  0.786 0.826   0.808  0.826  0.828
Histopathology skin - treated site(no examined)  5  5  5  5  5  5  5  5
Within normal limit  5  5  3  0  5  5  3  0
Hyperkeratosis  0  0  0  0  0  0  5
 Very slight  0  0  2  0  0  0  2  0
 Slight  0  0  0  5  0  0  0  5

No statistically significant differences identified (histopathology not statistically analyzed).

Applicant's summary and conclusion